Drug-resistant tuberculosis: Latest advances

The Lancet Respiratory Medicine

Volumn 1, Issue 1, 2013, Pages

  Falzon, Dennis ^a   Weyer, Karin ^a   Raviglione, Mario C ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; BEDAQUILINE; CAPREOMYCIN; DELAMANID; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ASIA; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BELARUS; DIAGNOSTIC ACCURACY; DRUG CONTROL; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; EASTERN EUROPE; GEOGRAPHIC DISTRIBUTION; GOVERNMENT REGULATION; HUMAN; INTERNET; LONG TERM CARE; LOWEST INCOME GROUP; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; SEROLOGY; SHORT COURSE THERAPY; SPUTUM CULTURE; TREATMENT DURATION; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; MULTIDRUG RESISTANCE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84880038471     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(12)70056-5     Document Type: Note

References (12)

1. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012, 54:579-581.
2. " Totally drug-resistant" tuberculosis: a WHO consultation on the diagnostic definition and treatment options-March 21-22, 2012 WHO, (accessed Dec 4, 2012). http://www.who.int/tb/challenges/xdr/xdrconsultation/.
3. Zignol M, van Gemert W, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012, 90:111. 19D.
4. Global tuberculosis report 2012 2012, WHO, World Health Organization, Geneva, Switzerland.
5. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012, 39:1425-1431.
6. Chang K, Lu W, Wang J, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect 2012, 64:580-588.
7. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012, 9:e1001300.
8. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011, 38:516-528.
9. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012, 56:3271-3276.
10. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012, 366:2151-2160.
11. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012, 380:986-993.
12. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012, 367:1508-1518.